Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works
- Conditions
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT05134987
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
DETERMINE: Detemir vs NPH
- Conditions
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 336
- Registration Number
- NCT05124457
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
MeDiGes Study: Metformine Use in Gestational Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2020-05-15
- Target Recruit Count
- 200
- Registration Number
- NCT04222348
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 12847
- Registration Number
- NCT03960814
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Bagsværd, Denmark
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT03377699
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 752
- Registration Number
- NCT03220425
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 609
- Registration Number
- NCT02967211
- Locations
- 🇮🇹
Investigational Site Number 380007, Forlì, Italy
🇮🇹Investigational Site Number 380012, Milano, Italy
🇮🇹Investigational Site Number 380026, Padova, Italy
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
- Conditions
- Interventions
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 705
- Registration Number
- NCT02967224
- Locations
- 🇮🇪
Investigational Site Number 372003, Dublin 4, Ireland
🇮🇪Investigational Site Number 327002, Dublin 7, Ireland
🇫🇷Investigational Site Number 250045, Montpellier, France
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)
- Conditions
- Interventions
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3304
- Registration Number
- NCT02451137
- Locations
- 🇺🇸
Investigational Site Number 840371, Los Angeles, California, United States
🇺🇸Investigational Site Number 840779, Cleveland, Ohio, United States
🇺🇸Investigational Site Number 840348, Pittsburgh, Pennsylvania, United States
A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin
- Conditions
- Interventions
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 13
- Registration Number
- NCT02162407
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.